You are here

Covid-19 drug to cost government entities US$2,340 for 5-day course

BT_20200630_NAHGILLEAD30_4160197.jpg
Gilead's chief executive Mr O'Day says Gilead wants to price Remdesivir in a way that would give patients access to it.

California

GILEAD Sciences said it will charge the US government and other developed countries US$390 per vial for its coronavirus-fighting drug Remdesivir, or about US$2,340 for a typical five-day course of treatment.

The company said in a statement on Monday that it would offer...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes